Intana Announces Agreement to Provide Proprietary Spectroscopy Technology
Intana Bioscience GmbH announced that it has entered an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium.
Under the agreement, Intana will provide its proprietary Fluorescent Cross Correlation Spectroscopy (FCCS) technology platform to screen for small molecule inhibitors of a set of target proteins. FCCS is a spectroscopic method to measure the interactions of molecules in solution, based on the sensitive detection of single molecules. The proprietary technology of Intana Bioscience allows FCCS to be performed in cellular lysates, thereby characterizing the interactions between small molecules and their target proteins in approximately physiological conditions. In the course of this collaboration, Intana will develop assays and establish a medium to high throughput screening platform for drug discovery projects at Janssen Pharmaceutica N.V. Additionally the technology will provide access to the binding kinetics of identified inhibitors, in support of lead optimization.
Intana Bioscience is a privately‐held biotechnology company based in Munich/Martinsried, Germany. As service provider Intana supports pharmaceutical and biotechnology companies in their drug discovery efforts using Fluorescence Cross Correlation Spectroscopy ‐ FCCS. The technology can be used to characterize drug target interactions with respect to affinity and kinetic parameters. Measurements can be carried out in cellular lysates, thereby circumventing tedious protein purification and providing physiological conditions for measurements. Customers benefit from short assay development times and precise affinity determination in a physiological environment. Intana receives seed financing by European investors BioM, High‐Tech Gründerfonds and Bayern Kapital.
About High-Tech Gründerfonds
High-Tech Gründerfonds invests venture capital in young, high-opportunity technological companies implementing promising research results in an entrepreneurial manner. The start-up companies are planned to lead their R&D projects to the production of a prototype or a “proof of concepts” or market launch by means of the seed financing of up to 500k EUR. The High-Tech Gründerfonds has a fund volume of around 272m EUR. Investors of the public-private partnership are the Federal Ministry for Economics and Technology, the KfW bank group as well as the six industrial groups BASF, Deutsche Telekom, Siemens, Robert Bosch, Daimler and Carl Zeiss.
High-Tech Gründerfonds Management GmbH
Dr. Michael Nettersheim
Phone: +49 228 96568500
Fax: +49 228 96568550